Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide
(OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in
Cynomolgus Monkeys
Hong Shen, Hong Su, Tongtong Liu, Ming Yao, Gabe Mintier, Lun Li, R. Marcus Fancher,
Ramaswamy Iyer, Punit Marathe, Yurong Lai, and A. David Rodrigues
Pharmaceutical Candidate Optimization (H.Shen., H.Su, T.L., M.Y., R.M.F., R.I., P.M., Y.L.,
A.D.R.), Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development,
Princeton, NJ; Department of Bioanalytical Service (L.L.), WuXi AppTec Co., Ltd, Shanghai,
China
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
2
Running title: Use of Cynomolgus Monkey to Assess DDIs Involving OATPs
Corresponding author: Hong Shen, F1.3802, Route 206 & Province Line Road, Bristol-Myers
Squibb Company, Princeton, NJ 08543-4000. Telephone: (609) 252-4509; Facsimile: (609) 252-
6802; E-mail: [email protected]
Number of text pages: 31
Number of tables: 5
Number of figures: 6
Number of references: 32
Number of words:
Abstract: 250
Introduction: 986
Discussion: 1,886
Abbreviations: ADME, absorption, distribution, metabolism, and excretion; ATV, atorvastatin;
AUC, area under the concentration-time curve; BDC, bile duct cannulated; Cmax, maximum
plasma concentration; cNTCP, cynolmogus monkey sodium-taurocholate cotransporting
polypeptide; cOATP, cynomolgus organic anion transporting polypeptide; CsA, cyclosporin A;
CYP, cytochrome P450; DDI, drug-drug interaction; fu, fraction of unbound drug; HBSS, Hank’s
buffered saline solution; HEK, human embryonic kidney-293; HEPES, N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid; HMG-CoA, 3-hydroxy-3-methylglutaryl-
coenzyme; hNTCP, human sodium-taurocholate cotransporting polypeptide; hOATP, human
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
3
organic anion transporting polypeptide; HPLC, high-performance liquid chromatography; IC50,
concentration required to inhibit transport by 50%; IS, internal standard; ITC, International
Transporter Consortium; IVIVE, in vitro-in vivo extrapolation; Ki, inhibitory constant; Km,
Michaelis-Menten constant that corresponds to the substrate concentration at which the uptake
rate is half of Vmax; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LSC, liquid
scintillation counting; PCR, polymerase chain reaction; RIF, rifampin; RSV: rosuvastatin; Vmax,
maximum transport rate.
Recommended section: Metabolism, Transport and Pharmacogenomics
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
4
Abstract
Organic anion transporting polypeptides (OATP) mediate hepatic drug uptake and serve as the
loci of drug-drug interactions (DDI). Consequently, there is a major need to develop animal
models and refine vitro-in vivo extrapolations. Therefore, the in vivo disposition of a model
OATP substrate, [3H]rosuvastatin (RSV), was studied in the cynomolgus monkey and reported
for the first time. Following a 3 mg/kg oral dose, mass balance was achieved following bile duct
cannulation (mean total recovery of radioactivity of 103.6%). Forty-two % of the RSV dose was
recovered in urine and bile, and the elimination pathways were similar to those reported for
human subjects; 61.7%, 39.0% and 2.9% of the dose was recovered in the feces, bile and urine,
respectively. The high levels of unchanged RSV recovered in urine and bile (26% of the dose),
and the relatively low levels of metabolites observed, indicated that RSV was eliminated largely
by excretion. Also for the first time, the in vitro inhibitory potential of cyclosporin A (CsA)
towards cynomolgus monkey OATPs and sodium-taurocholate co-transporting polypeptide
(NTCP) was studied in vitro (primary hepatocytes and transfected transporters). It is concluded
that one can study the CsA-RSV DDI in the cynomolgus monkey. For example, the in vitro IC50
values were within 2-fold (monkey vs. human) and the increase (vs. vehicle control) in RSV
AUC0-inf (6.3-fold) and Cmax (10.2-fold) with CsA (100 mg/kg) was similar to that reported for
humans. The results further support the use of cynomolgus monkey as a model to assess
interactions involving OATP inhibition.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
5
Introduction
Rosuvastatin (RSV) is a 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase
inhibitor (i.e., statin) used in the treatment of patients with hypercholesterolemia. DDIs involving
RSV that result in an increase in its systemic exposure might result in unwanted side effects
including myopathy and rhabdomyolysis. Such DDIs are clinically significant when one
considers that known transporter inhibitors like CsA increase RSV area under the plasma drug
concentration-time curve (AUC) and maximum plasma concentration (Cmax) 7.1- and 10.6-fold,
respectively (Simonson et al., 2004). Because RSV is not significantly metabolized across
several species (Martin et al., 2003b; Nezasa et al., 2002b) and is selectively transported and
distributed into the liver (Martin et al., 2003a; Martin et al., 2003b; Nezasa et al., 2002a; Nezasa
et al., 2002b), the overall disposition profile of oral RSV is thought to be highly dependent on
drug transporters such as OATP, NTCP, and breast cancer resistance protein (BCRP) (Bi et al.,
2013; Ho et al., 2006; Keskitalo et al., 2009; Kitamura et al., 2008; Pasanen et al., 2007). It has
been established that hepatic clearance and renal clearance are the primary pathways for the
elimination of RSV, account for 72 and 28% of total body clearance, respectively (Martin et al.,
2003a). Active transport processes are responsible for approximately 90% of total hepatic uptake
clearance of RSV. Indeed, RSV is a substrate of the hepatic OATP1B1 and OATP1B3 in vitro,
the former contributing 77% and the latter 23% to sodium-independent active uptake in human
hepatocytes. The contribution of both OATPs represents 70% of total hepatic active uptake; the
remaining active uptake (30%) is attributed to to NTCP (Bi et al., 2013; Ho et al., 2006;
Kitamura et al., 2008). Consistent with the contribution of individual transporters to the overall
hepatic uptake of RSV, OATPs and NTCP comprise two of the most abundant sinusoidal uptake
transporters in human liver tissues, with relative abundance of quantifiable hepatic transporters
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
6
of 29% and 13%, respectively, when quantified transporter protein expression in a human liver
bank (n = 55) by liquid chromatography tandem mass spectrometry (LC-MS/MS) (Wang et al.,
2015). Furthermore, for most transporters, the expression in the liver tissues was comparable to
that in the cryopreserved hepatocytes (Wang et al., 2015). In addition to in vitro assessment,
RSV has often been used for kinetic studies in vivo in several species, including humans
(Prueksaritanont et al., 2014; Schneck et al., 2004; Simonson et al., 2004), monkeys (Shen et al.,
2013), mice (Salphati et al., 2014), rats (Wen and Xiong, 2011), and pigs (Bergman et al., 2009).
When compared to rodents, however, the absorption, distribution, metabolism, and excretion
(ADME) profile of RSV in non-human primates has not been studied extensively (Martin et al.,
2003b; Nezasa et al., 2002b).
It has been reported that cynomolgus monkey OATPs (cOATPs) share a high degree of
amino acid sequence identity and functional similarity to their human counterparts (Shen et al.,
2013; Takahashi et al., 2013). Concomitant with these identities and similarities, there are
investigations employing the cynomolgus monkey as an in vivo preclinical model to assess
OATP DDIs (Shen et al., 2013; Takahashi et al., 2013). The DDIs have been investigated in
other animal models; however, the sequences and transporting profiles obtained for xenobiotics
in other animal species are frequently different to those obtained in humans, reducing the utility
of such animals (Li et al., 2013; Shirasaka et al., 2010; Shitara et al., 2003). In fact, there is only
one member of the OATP1B family, Oatp1b2, which is the closest ortholog of both human
OATP1B1 and OATP1B3 (hOATP1B1 and hOATP1B3) and likely arises from a gene
duplication after divergence of the rodent species (Hagenbuch and Meier, 2004). The comparison
of predicted Oatps in the genomes of dog, cow and horse suggested that there is only a single
Oatp in the 1B family, while cynomolgus monkey, a species much closer related to humans, both
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
7
cOATP1B1 and cOATP1B3 orthologs have been cloned. (Shen et al., 2013). These results
indicate that, for many drugs, cynomolgus monkey may represent an acceptable in vitro and in
vivo model to investigate OATPs.
Several reports have described various rodent models, which can be used to support the
investigation of OATPs in vivo. For example, it is possible to delete the murine Oatp1b2 gene
(Chang et al., 2014; Lu et al., 2008; Zaher et al., 2008), introduce human OATP genes (van de
Steeg et al., 2009), and develop combinations of OATP knockout and knockin (Higgins et al.,
2014; Salphati et al., 2014). However, the interpretation of data obtained with such models can
be difficult in some cases, when compensatory mechanisms are suspected (Iusuf et al., 2014;
Klaassen and Lu, 2008; Salphati et al., 2014). In addition, quantitative translation of data
obtained with knockout and/or knockin animals can be challenging. Indeed unexpected results
have been observed in mice and rats compared to humans. For example, the blood and liver
concentrations of atorvastatin in Oatp1a/b knockout mice were similar to wild type animals
(Chang et al., 2014). The expression of human OATP1B1 and OATP1B3 in the humanized mice
did not significantly alter the liver or plasma concentration ratios of RSV and pitavastatin
compared to Oatp1a/1b knockout controls (Salphati et al., 2014). Therefore, there is a need for a
better preclinical model to enable the prediction of OATP-mediated drug disposition and DDIs.
As described herein, the ADME of RSV was studied after administration of oral [3H]RSV
(3 mg/kg) to BDC cynomolgus monkeys. Because RSV has been shown to be a substrate of
human OATPs and sodium-taurocholate co-transporting polypeptide (NTCP) (Bi et al., 2013),
we investigated CsA as an inhibitor of both monkey OATP- and NTCP-mediated RSV uptake in
vitro. Finally, the CsA-RSV DDI was studied in vivo in cynomolgus monkeys. Our results
indicate that there is a consistency in the elimination pathway of oral RSV between human and
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
8
cynomolgus monkey, and that the monkey can be used as a model to assess inhibition of OATP
both in vitro and in vivo.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
9
Materials and Methods
Chemicals, Hepatocytes and Cynomolgus Monkeys. All chemicals and solvents of reagent
or high-performance liquid chromatography (HPLC) grade were purchased from Sigma-Aldrich
(St. Louis, MO) unless otherwise stated. Nonradiolabeled RSV was purchased from Toronto
Research Chemicals Inc. (Toronto, ON, Canada), CsA oral solution (Neoral, 100 mg/mL) was
purchased from Novartis Pharmaceuticals Corporation (East Hanover, NJ). [3H]Taurocholic acid
(TCA) (5.0 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Waltham,
MA). [3H]RSV calcium (10.0 mCi/mmol) and [3H]atorvastatin (ATV) sodium (20.0 mCi/mmol)
were obtained from American Radiolabeled Chemicals (St. Louis, MO). Radiochemical purity of
all compounds was determined to be greater than 98.2% by HPLC. Cell culture media and
reagents were purchased from Invitrogen (Carlsbad, CA) or Mediatech, Inc (Manassas, VA).
Cryopreserved male human and cynomolgus hepatocytes were purchased from
BioreclamationIVT (Baltimore, MD). The 24-well poly-D-lysine coated plates were purchased
from BD Biosciences (San Jose, CA). Intact and BDC male cynomolgus monkeys were procured
from Charles River Laboratories, Inc. (Wilmington, MA). All monkey excreta, bile, blood and
plasma were collected gravimetrically and stored at -20°C until analysis.
BDC Cynomolgus Monkey Study. All animal studies were performed under the
standards recommended by the Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, 1996) and were approved by BMS Institutional Animal Care and
Use Committee. The excretion of radioactivity into bile, feces, and urine and metabolism of RSV
was investigated in BDC male cynomolgus monkeys (Charles River Laboratories, Inc.) after
administration of [3H]RSV. BDC monkeys (N = 3, weighing approximately 5.5 to 6.5 kg) were
individually housed in metabolism cages and were freely mobile during the entire study with the
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
10
exception of brief manual restraint for oral dosing. Each animal received a single oral dose of
[3H]RSV administered by gavage at a dose level of 3 mg/kg (approximately 15 µCi/kg). Animals
were fasted overnight before dosing. Approximately 4 hr after dosing, animals were fed Certified
Primate Diet 5048 (PMI Nutrition International, Inc.). Bile was collected before dosing and from
0 to 8, 8 to 24, and 24 to 72 hr after dosing into containers that were surrounded by dry ice. Urine
and feces were collected before dosing and over 24 hr intervals through 168 hr postdose. Blood
samples were collected into tubes containing K2EDTA from the femoral artery before dosing and
at 1, 2, 6, 12, 24, and 48 hr after dosing. The blood samples were then centrifuged to obtain
plasma, and the plasma samples were frozen at –70°C until analysis.
Determination of Radioactivity in Biological Matrices from BDC Cynomolgus
Monkeys. Plasma, urine, bile and fecal samples were analyzed for radioactivity concentration
using Liquid Scintillation Counting (LSC). Portions of plasma (50-100 µL), urine (50 µL) and
bile (10 µL) were mixed with 5 mL Ecolite scintillation cocktail (PerkinElmer Life and
Analytical Sciences, Waltham, MA) into polystyrene tubes. For fecal samples, two portions
(approximately 0.2 g each) of fecal homogenate were weighed individually in a scintillation vial,
mixed with 1 mL Soluene-350 and shaken slowly at room temperature overnight. The solubilized
homogenate mixtures were bleached with 1 mL 20% hydrogen peroxide, and then neutralized
with 0.1 mL of a solution containing saturated sodium pyruvate in methanol, glacial acetic acid
and methanol (4:3:1, by volume). After addition of EcoliteTM cocktail, the samples were mixed
and stored under refrigerated conditions in the dark overnight. Radioactivity was determined by
LSC6000 or LS6500 liquid scintillation counter (Beckman Coulter, Inc., Fullerton, CA) for 5
min.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
11
Metabolite Profiling of Cynomolgus Monkey Bile and Urine. Pooled bile and urine
samples from BDC monkeys were prepared by combining a constant percentage of bile and urine
volume across animals (3% and 2%, respectively). The pooled samples were then centrifuged at
14,000 g for 5 min. A portion of supernatant (25-50 µL) was injected into the HPLC for
biotransformation profiling and mass spectral analysis.
HPLC analysis was conducted on an Agilent 1290 Infinity LC system (Agilent
Technologies, Palo Alto, CA) interfaced to a Linear Ion Trap (LTQ) mass spectrometer (Thermo
Fisher Scientific, Waltham, MA). Separation was achieved on a Agilent Zorbax SB-C18 column
(4.6 mm × 250 mm, 5 µm) using a mobile phase consisting of 0.1% formic acid and 0.1%
acetonitrile in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) at a constant
flow rate of 0.8 ml/min. The gradient was as follows: 0–5 min, 20% B; 40 min, 25% B; 47 min,
50% B; 50 min, 90% B; and 60 min, 20%. The HPLC eluate was split via a Gilson Model FC
204 fraction collector (Gilson, Middleton, WI), with which 25% of the eluate was directed into
LTQ mass spectrometer for profiling. The remaining 75% of the eluate was collected into
ScintiPlate™-96-well plates at 0.2-min intervals per well. EcoliteTM scintillation cocktail (200
µL) was then added to each well, and the radioactivity was counted for 20 min per well with a
PerkinElmer 1450 MicroBeta Wallac TRILUX Liquid Scintillation and Luminescence Counter
(PerkinElmer Life and Analytical Sciences, Waltham, MA). Radiochromatographic profiles were
prepared by plotting the net counts per minute values obtained from the counter versus time after
injection. Mass spectral analyses were performed using electrospray ionization in the positive ion
mode. Capillary temperature was 300°C and the electrospray ionizing voltage was maintained at
4.5 kV for all analyses. The collision energy was 15.0% for liquid chromatography-tandem mass
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
12
spectrometry (LC-MS/MS) analysis. Other instrument parameters were adjusted to give
maximum sensitivity or fragmentation of drug-related components.
Generation of Stably Expressed Cynomolgus Monkey NTCP in HEK-293 Cells.
Cloning and stable transfection of HEK-293 cells with cynomolgus monkey NTCP (cNTCP)
were carried out as described previously (Shen et al., 2013). In brief, cNTCP was cloned out of
cDNA synthesized from Mauritian cynomolgus monkey liver total RNA. For polymerase chain
reaction (PCR) on double-stranded cDNA from monkey liver, the following degenerate
oligonucleotides, derived from the human and rhesus monkey NTCP gene sequences and
predicted cynomolgus NTCP transcript sequence, were used: 5’-CTT CCA CTG CCT CAC
AGG AGG-3’ (forward primer, corresponding to the nucleotide positions 114-134 of human
NTCP cDNA NM_003049.3), 5’-AAG GGC TAG GCT GTG CAA GG-3’ (reverse primer,
reverse complementary to positions 1170-1189). PCR products were cloned into pJet1.2
(Fermentas) and several clones for each cDNA were sequenced. Sequences were deposited to
GenBank: cynomolgus monkey NTCP (ACC# KP453714). The coding sequence of the cDNA
was subcloned into the Gateway entry vector pDONR221 (Invitrogen, Carlsbad, CA) using
standard methods. The Gateway entry clones were recombined into a Gateway adapted version
of the expression vector pcDNA5/FRT/TO (Invitrogen, Carlsbad, CA) using LR clonase II
(LifeTechnologies, Carlsbad, CA) according to the manufacturer’s protocol. Expression
constructs were analyzed by agarose gel electrophoresis and the sequence was confirmed.
Flp-In HEK-293 cells were cultured in Dulbeccos’s modified eagle’s medium,
supplemented with 10% fetal bovine serum, 0.1 mM nonessential amino acids, and 2 mM L-
glutamine, on a 6-well plate as described (Shen et al., 2013). After washing with serum-free
medium, the culture well was incubated at 37 °C for 4 h with 1 mL serum-free medium which
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
13
contained 10 µL Lipofectamine 2000 (Invitrogen; Carlsbad, CA) and 2.5 µg plasmid DNA. The
cells stably transfected with pcDNA5/FRT/TO/cNTCP were then selected using hygromycin B
(200 μg/ml) according to the protocol of the vendor (Invitrogen; Carlsbad, CA). Expression of
cNTCP was verified by RT-PCR and functional characterization.
Uptake Studies Using Transporter-Expressing HEK-293 Cells. The HEK-293 cells
individually expressing human OATP1B1 (hOATP1B1), hOATP1B3, cynomolgus monkey
OATP1B1 (cOATP1B1), cOATP1B3, or cNTCP were prepared and used as described
previously (Shen et al., 2013). In brief, all transporter- and vector-transfected cells were cultured
at 37°C in an atmosphere of 95% air and 5% CO2 and sub-cultured once a week. Cells were
seeded in 24-well poly-D-lysine coated plates at a density of 5 x 105 cells per well, and were
ready for experiment after 48 to 72 h. Before uptake experiments, cells were washed twice with
1.5 ml of pre-warmed Hank’s buffered saline solution (HBSS). The cells were then preincubated
with uptake buffer (HBSS with 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
(HEPES), pH 7.4) containing CsA only (0.023 to 16.7 µM), at 37 °C for 15 min. Subsequently,
the cells were incubated with the test solution, containing CsA and the substrate RSV (0.1 µM) at
37 °C for 2 min. Over this time period, linearity of uptake has been confirmed (unpublished
data). Cells were washed three times with 1 ml of ice-cold HBSS buffer and lysed with 0.3 ml of
0.1% Triton X-100. Intracellular accumulation of RSV was determined using LC-MS/MS as
described later. Assessment of uptake of [3H]TCA, [3H]RSV, and [3H]atorvastatin (ATV) into
HEK-293 cells expressing cNTCP involved a 5 min incubation. The cells were lysed with 0.3 ml
of 0.1% Triton X-100, and the radioactivity was determined by liquid scintillation counting.
Accumulation was normalized to the protein content of the HEK-293 cells in each well measured
using a bicinchoninic acid assay (BCA Protein Assay Kit; Pierce Chemical, Rockfold, IL).
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
14
LC-MS/MS Analysis of RSV in Cell Lysates from In Vitro Transporter Studies.
Cells were solubilized and lysed in 300 µL of 0.1% Triton X-100 in water. After 60 min
incubation at room temperature, the samples were transferred by a Tecan liquid handler from a
24 well plate to the first 96 well filter plate for LC-MS/MS analysis and the second 96- well plate
for protein measurement. Protein concentrations in the cell lysates (20 µL) were measured using
the BCA protein assay kit (Pierce Chemical, Rockfold, IL). The lysed samples (150 µL) were
mixed with 200 µL of acetonitrile containing d6-rosuvastatin, the internal standard (IS), in a 96-
well hydrophilic filter plate (Millipore; Billerica, MA), stacked with a deep 96-well receiver
plate and centrifuged. The filtrates were dried under stream of nitrogen to half of the initial
volume in the receiver plate, votexed and analyzed by LC-MS/MS. Cellular uptake was
normalized to the protein content.
The liquid chromatography system was the Shimadzu SCL 30AD Nexera comprised of
two LC-30AD pumps and a Shimadzu SIL-30AC autosampler. RSV and d6-rosuvastatin were
separated under gradient elution on a Waters Acquity HSS T3 (50 mm× 2.1 mm internal
diameter, 1.8 μm particle size) (Waters, Santa Clara, CA, USA). The column was maintained at
room temperature. The mobile phase was a mixture of 0.1% formic acid (A) and acetonitrile (B)
at a flow rate of 0.60 mL/min. The gradient program was set as follows: from 0 min to 0.01 min,
keep B for 20%, from 0.01 min to 2.0 min, increase B linearly from 20% to 60%; from 2.0 min
to 2.1 min, increase B linearly from 60% to 95%, maintain 95% B for 0.4 min, from 2.5 to 2.6
min, decrease B from 95% to 20%. Then equilibrate column for 0.9 min for next injection. The
retention time for rosuvastatin and d6-rosuvastatin was 1.86 min. An AB Sciex Qtrap 6500
system (Applied Biosystems/MDS Analytical Technologies, Foster City, CA, USA) equipped
with electrospray ionization source was used for mass spectrometric detection. AnalystTM
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
15
version 1.62 was used as the data acquisition software. The electrospray ionization source was
used in the positive ion mode. The LC-MS/MS detector was operated at unit resolution in the
multiple reaction monitoring mode using the transitions of the protonated forms of RSV at m/z
482.1>258.07 and d6-rosuvastatin at m/z 488.16>263.9. Optimized parameters were as follows:
curtain gas, gas 1 and gas 2 (nitrogen) 60 and 75 units, respectively; dwell time 100 ms; source
temperature 400 ºC; IonSpray voltage 5000 V. Declustering potential and collision energy were,
116 V and 45 eV for both RSV and d6-rosuvastatin.
In addition, a divert valve was used to minimize the triton X100 introduced into the MS
source. At 0 to 0.8 min, the ultra performance liquid chromatography eluant was diverted to
waste and switched to MS source after one min. After 3.0 min, eluent was diverted back to waste
again. The range of standard curve was between 0.02 to 10.0 nM for RSV.
Uptake Studies in Cryopreserved Hepatocytes. Cryopreserved human (Lots OJE, GST,
LIO) and cynomolgus monkey hepatocytes (pool of four males; Lot VCE) were thawed
according to the manufacturer’s instructions and resuspended in InVitroGRO Krebs-Henseleit
buffer (KHB) (BioreclamationIVT; Baltimore, MD). Human hepatocytes from three donors were
then pooled together after thawing. Cell number and viability were assessed using trypan blue
exclusion. Cells with viability greater than 80% at the time of uptake assay were selected to
reduce the background signal, and resuspended at a concentration of 2x106 viable cells/mL in
InVitroGRO KHB. Centrifuge tubes (0.4 mL) were prepared by filling with 50 μL of 3N KOH
solution and layering 100 μL of filtration oil on top of the KOH. The filtration oil was prepared
as a mixture of 82 parts silicone oil to 18 parts mineral oil, resulting in an oil mixture with a
density of 1.015 g/mL. Cell suspensions (100 µL) containing appropriate concentrations of CsA
were added to glass tubes and preincubated in a water bath at 37°C for 5 min. Uptake studies
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
16
were initiated by an addition of 80 µL prewarmed buffer containing [3H]RSV (0.2 µM). Aliquots
(100 µL) of the mixture were removed at 15 and 90 sec, and then transferred to centrifuge tubes
and layered carefully on top of an oil layer. The tubes were centrifuged immediately at 13,000xg
for 15 sec. Following centrifugation of hepatocytes through the oil layer, the cell suspension
buffer containing RSV was left in the supernatant. The centrifuge tubes were incubated for at
least 2 h at an ambient temperature, and frozen in a -80°C freezer or on dry ice just prior to
cutting. The tubes were cut in the middle of the oil layer, allowing the bottom section to drop
into a 20 mL scintillation vial. The cell pellets were resuspended in 150 µL 2N HCl to neutralize
the solution and read in a scintillation counter after addition of the scintillation cocktail.
In vivo DDI study. The in vivo DDI pharmacokinetic studies were conducted by WuXi
AppTec Corporation (Suzhou, China) using 3 young adult male cynomolgus monkeys weighing
between 3.4 and 4.2 kg. The animals were housed in a temperature- and humidity-controlled
room with a 12-h light/dark cycle. Animals were fed approximately 120 grams of Certified
Monkey Diet daily (Beijing Vital Keao Feed Corporation; Beijing, China). The monkeys were
fasted for a 12 h prior to dose administration, and water was made available ad lib. In the first
period, three monkeys received an oral dose of RSV at 3 mg/kg of body weight dissolved in
sterile water by oral gavage followed by a water rinse. Following a 1-week washout period, the
same animals were administered an equivalent oral dose of RSV one hour after CsA
administration (100 mg/kg, PO; Neroral cyclosporine oral solution) in the second period. There
was no substantial weight fluctuation of the animals between the times of RSV alone and
coadministration.
Approximately 1 milliliter of blood was collected in tubes containing potassium (K2)
EDTA by venipuncture via the cephalic or saphenous veins at 0.25, 0.5, 0.45, 1, 2, 3, 5, 7, 24 and
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
17
48 h after RSV administration. In period 2 (i.e., coadministration treatment), 300 μL of whole
blood was aliquoted and stored at ≤ -15°C for CsA analysis. The remaining blood volume was
centrifuged (3,000 x g for 10 min at 2 to 8°C) within one hour of collection, transferred into
polypropylene microcentrifuge tubes and stored frozen at -70°C. The animals were placed in
metabolic cages, and urine was collected at 0-7, 7-24 and 24-48 hs post-dose into containers
cooled by wet ice. Total volume of urine samples for different periods were measured at the end
of collection and recorded. Aliquots (5mL) of urine samples collected from each period were
frozen on dry ice and kept at -70°C until analysis.
LC-MS/MS analysis of RSV in plasma and urine. Stock solution (1 mg/mL) of RSV
was prepared in acetonitrile / 0.1 M ammonium acetate pH 4.0 buffer (80:20 v/v). Stock solution
(1 mg/mL) of rosuvastain-5S-lactone, a metabolite of RSV, was prepared in acetonitrile/0.1M
ammonium acetate pH 4.0 buffer (50:50 v/v) and stock solution (0.2 mg/mL) of atorvastatin (IS)
was prepared in 50% acetonitrile. For plasma assay, the following RSV calibration standards
were prepared in monkey plasma: 0.1, 0.2, 1, 10, 50, 100, 200 and 250 ng/mL. Quality control
(QC) samples were also prepared in monkey plasma at 0.3, 5, 90 and 190 ng/ml. For urine assay,
the RSV calibration standards were prepared in monkey plasma at 0.3, 0.6, 3, 30, 150, 300, 600
and 750 ng/mL. QC samples were prepared in monkey urine with 0.75 mg/mL Triton X-100 at
4.5, 75, 1350 and 2850 ng/mL, and diluted with plasma (1:4, urine:plasma v/v) and quantified by
plasma calibration curve.
Plasma sample extraction for RSV was conducted in 96-well plates using protein
precipitation with acetonitrile containing 0.5% formic acid. In brief, 50 μL of calibration
standards, QC samples and study samples were first mixed with 50 μL of chilled (ice/water bath)
0.1M ammonium acetate buffer (pH 4.5) followed by 20 μL of chilled 100 ng/mL atorvastatin
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
18
solution in acetonitrile / 0.1M ammonium acetate pH 4.0 buffer (75:25 v/v). Following addition
of 300 μL chilled 0.5% formic acid in acetonitrile, vortex-mixing, and centrifugation at 4°C, an
aliquot of 300 μL of each sample was transferred to a new 96-well plate, evaporated to dryness
under N2 at RT, and reconstituted with 200 μL chilled acetonitrile /0.1M ammonium acetate pH
4.0 buffer (50:50 v/v). A 10-μL aliquot was injected for analysis by LC-MS/MS.
Urine sample extraction for RSV was conducted in 96-well plates using protein
precipitation with acetonitrile containing 0.5% formic acid. In brief, 50 μL of calibration
standards, diluted QC samples and diluted study samples were first mixed with 50 μl of chilled
(ice/water bath) 0.1M ammonium acetate buffer (pH 4.5) followed by 20 μL of chilled 100
ng/mL atorvastatin solution in acetonitrile/0.1M ammonium acetate pH 4.0 buffer (75:25 v/v).
Following addition of 300 μL chilled 0.5% formic acid in acetonitrile, vortex-mixing, and
centrifugation at 4°C, an aliquot of 200 μL of each sample was transferred to a new 96-well
plate. Chilled acetonitrile/0.1M ammonium acetate pH 4.0 buffer (200 µL) (50:50 v/v) was
added and a 10-μL aliquot was injected for analysis by LC-MS/MS.
The HPLC system consisted of an Agilent 1200 pump, Agilent 1200 column oven
(Agilent Technologies, Santa Clara, CA) and a CTC PAL autosampler (CTC Analytics AG,
Zwingen, Switzerland) maintained at 4°C during analysis. The analytical column used was a
Shiseido CAPCELLPAK MG C18 (2.0 x 50 mm, 5.0 μm) (Shiseido Co., Japan) and was
maintained at 40°C. The mobile phase consisted of ammonium acetate pH 4.0 buffer (eluent A)
and 100% acetonitrile (eluent B). The following gradient elution was used: start and maintain at
30% B from 0 to 0.5 min; ramp from 30 to 70% B from 0.5 to 1.5 min; hold at 70% B from 1.5
to 2.5 min; ramp to 30% B from 2.5 to 2.51 min; hold at 30% B until 3.7 min before the next
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
19
injection. The flow rate was 0.4 mL/min. The retention times of RSV and atorvastatin were 2.15
and 2.50 min, respectively.
The HPLC was interfaced to a Sciex API 5000 mass spectrometer (MDS Sciex, Concord,
ON). The following positive electrospray source/gas conditions were used: curtain gas at 25; ion
spray voltage at 5500; temperature at 550°C; ion source gas 1 at 40; ion source gas 2 at 50. The
compound-dependent parameters used for RSV and atorvastatin were, respectively, as follows:
decluster-ing potential of 80, 80; collision energy of 48, 30; collision cell exit potential of 14, 14.
The multiple reaction monitoring transitions used were as follows: m/z 482.2→m/z 258.1 for
RSV, and m/z 559.3→ m/z 440.2 for atorvastatin.
To avoid the conversion of rosuvastatin-5S-lactone metabolite to RSV, plasma samples
stored were thawed at 4°C (ice/water), and the aliquots for analysis were mixed with a pH 4.5
buffer. For the same reason, the acetonitrile used for protein precipitation and the reconstitution
solution were also acidified. To avoid assay bias due to potential conversion of the metabolite in
the mass spectrometer, the chromatographic conditions were optimized to achieve separation of
the lactone metabolite from rosuvastatin. In addition, a special QC sample containing only
rosuvastain-5S-lactone (lactone-only QC) was included in every sample analysis run to gauge
any conversion of the metabolite to RSV. The performance of this QC showed that the
conversion was minimal (less than 5%) ensuring no contribution to the measured RSV
concentrations.
LC-MS/MS Analysis of CsA in Blood. Stock solutions of CsA (0.2mg/mL) and of
Cyclosporine A-13C2,d4 (1 mg/mL, IS) were prepared in methanol/acetone: (50:50 v/v). The
concentrations of CsA calibration standards prepared in monkey whole blood were: 1, 2.5, 10,
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
20
25, 100, 400, and 1500 ng/mL. The QC samples were prepared in monkey whole blood at
concentrations of 3, 40, 400 and 1200 ng/mL.
Whole blood sample extraction for CsA was conducted in polypropylene tubes using
protein precipitation with methanol/ acetonitrile (50:50 v/v). In brief, 450 µL of methanol/
acetonitrile (50:50 v/v) was added into each polypropylene tube, mixed with 50 µL of CsA-
13C2,d4 (IS) in methanol/ acetonitrile (50:50 v/v) followed by 50 µL sample. After vortex-mixing
and centrifugation at room temperature, an aliquot of 200 μL supernatant of each sample was
transferred to a 96-well plate, 200 μL of methanol/ acetonitrile (50:50 v/v) was added and mixed.
A 20-μL aliquot was injected for analysis by LC-MS/MS.
The HPLC system consisted of Agilent 1200 HPLC pump, Agilent 1200 column oven
and a CTC PAL autosampler maintained at 20°C. The analytical column used was a Venusil
XBP-C8, 5 µm (2.1 mm I.D. x 50 mm) (Agela) and was maintained at 80°C. The mobile phase
consisted of 0.2% acetic acid in water (eluent A) and 0.2% acetic acid in acetonitrile (eluent
B).The following gradient elution was used: start at 40% B, ramp from 40% to 100% B from 0.0
to 1.2 min; hold at 100% B from 1.2 to 2.0 min; ramp to 40% B from 2.0 to 2.1 min; hold at 40%
B until 2.8 min before the next injection. The flow rate was 0.6 mL/min. Retention times of CsA
and CsA-13C2,d4 were 1.54 and 1.54 min, respectively.
The HPLC was interfaced to a Sciex API 5000 mass spectrometer (MDS Sciex). The
following positive ESI source/gas conditions were used: curtain gas at 20; ion spray voltage at
5500 V; temperature at 500°C; ion source gas 1 at 60; ion source gas 2 at 20. The compound-
dependent parameters used for CsA and CsA-13C2,d4 were, respectively, as follows: declustering
potential of 140,140; collision energy of 25,25; collision cell exit potential of 10,10. The multiple
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
21
reaction monitoring transitions used were as follows :m/z 1219.45→m/z 1202.70 for CsA and
m/z 1225.45→m/z 1208.70 for CsA-13C2,d4.
Data Analysis. Within the in vitro transporter studies, each assay was conducted in
triplicate. The active transport of RSV by hOATP and cOATP was calculated after subtracting
the uptake in mock-transfected cells from the total uptake in the transporter-expressing cells. IC50
values, the concentration of CsA required for 50% inhibition of transport of RSV, were
calculated with WinNonlin (Pharsight Inc.; Mountain View, CA) using following equation:
where V is defined as the rate of RSV transport measured at given CsA concentration, γ is the
slope factor, C is the CsA concentration, V0 refers to the rate of RSV transport measured in the
absence of CsA, and Imax refers to the maximum inhibitory effect.
For the inhibition studies employing hepatocytes, the uptake rate of RSV (V(x-y);
pmol/min/106cells), determined from time x to time y (where y = 0.25 min when x = 1.5 min; or y
= 15 sec when x = 90 sec), was calculated using following equation:
IC50 values were then estimated by fitting V, the hepatic uptake at different CsA
concentrations, to the equation above using WinNonlin.
⎟⎟⎠
⎞⎜⎜⎝
⎛
+•
−=λγ
γ
CIC
CIVV
50
max0
( )yx
VVV yx
−−
=
y)-x(
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
22
For the pharmacokinetic analysis, noncompartmental analysis of RSV and CsA
concentration-time data was performed and the following standard parameters were estimated
using Kinetica (Thermo Fisher Scientific, Waltham, MA):
where CL/F and Vd/F are apparent clearance and volume of distribution after oral administration,
MRT is mean residence time, CLR is renal clearance, and Xe, 0-48 hr is amount recovered in urine
over 48 hr. AUC(0-48 hr) was calculated using the log-linear-trapezoidal method. AUC(0-inf) was
calculated as the sum of AUC(0-48 hr) and Ct/λ, where λ is the apparent terminal rate constant and
Ct is the predicted concentration at last time point. For each animal, λ was calculated by
regression of the terminal log-linear portion of the plasma concentration-time profile, and the
apparent terminal elimination half-life (t1/2) was calculated as the quotient of the natural log of 2
(ln [2]) and λ. The geometric mean ratio (GMR) and its 90% confidence interval (CI) were
calculated by calculating the arithmetic difference of the log means and its associated 90% CIs
and then exponentiating these results back to the original (GMR) scale. The t-distribution was
assumed in the calculation of all.
hr) 48(0-
hr 480- e,R
inf)0(d
inf)0(
MRTDose /F
Dose /F
AUC
XCL
AUCV
AUCCL
=
•=
=
−
−
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
23
Results
Excretion of Radioactivity in Bile, Urine and Feces of Cynomolgus Monkeys.
Recovery of radioactivity in bile, urine and feces was complete (103.6± 27.5%) by 168 hours
after administration of a single oral dose of [3H]RSV (3 mg/kg) to male BDC cynomolgus
monkeys (Table 1). Fecal excretion was major and accounted for 61.7 ± 25.1% of the dose
(Table 1). The balance was recovered in bile and in urine with 39.0 ± 3.0% and 2.9 ± 1.3% of the
radioactive dose, respectively. Approximately 90% of the biliary excretion was complete
between 0 and 24 hours with evidence of slower excretion beyond this time (0-24 hr vs. 24-72
hr: 34.3% vs. 4.7%). A majority of fecal excretion occurred by 72 hours. Although the urinary
excretion was small compared to biliary excretion, it continued up to the final collection period
(0-24 hr vs. 24-72 hr vs. 72-68 hr: 1.6% vs. 0.8% vs. 0.6%), indicating a slower rate of excretion
for a fraction of the dose (Table 1).
The radioactivity in the pooled bile and urine samples was analyzed by radio-HPLC. In
the pooled bile collected from 0 to 72 hr, unchanged RSV was the predominant component,
accounting for, on average, 62.8% of the sample radioactivity and 24.5% of the dose (Figure
1A). In addition to RSV, several metabolites were detected which accounted for 26% of the
sample radioactivity (Supplemental Figures 1 and 2). A similar chromatogram was obtained
from the pooled urine samples, as unchanged RSV was the main radioactive compound
accounting for 45.7% of the sample radioactivity (Figure 1B). Metabolites accounted for 37.2%
of the sample radioactivity and additional trace peaks were detected compared to biliary
chromatogram (Supplemental Figures 1 and 3).
CsA as an Inhibitor of RSV Uptake Mediated by cOATP and cNTCP. CsA was
evaluated as an inhibitor of RSV (0.1 µM) uptake after incubation with HEK-293 cells
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
24
containing individually expressed human and monkey OATP1B1 and OATP1B3 and monkey
NTCP. In these studies, cells were preincubated with CsA (0.02 to 16.7 µM) at 37°C for 15 min
before the addition of RSV. CsA inhibited uptake for hOATP1B1, hOATP1B3, cOATP1B1,
cOATP1B3, and cNTCP with an estimated IC50 of 0.21 ± 0.10 µM, 0.13 ± 0.06 µM, 0.28 ± 0.11
µM, 0.25 ± 0.09 µM, and 3.9 ± 2.0 µM, respectively (Figures 2 and 3A; Table 2). In addition, the
expression of cNTCP was confirmed at a functional level by measuring the uptake of human
NTCP model substrates (TCA, RSV and ATV) into the HEK-293 cells transfected with cNTCP
compared to the mock cells (Figure 3B).
Parallel experiments were also conducted to evaluate the inhibitory effects of CsA on the
uptake of 0.1 µM [3H]RSV in human and cynomolgus monkey hepatocytes (Figure 4).
Consistent with being a potent inhibitor of human and monkey OATPs using transporter-
overexpressing cells, CsA demonstrated significant concentration-dependent inhibition of RSV
uptake in human and monkey hepatocytes (maximal ~80% inhibition) with IC50 values of 0.30 ±
0.08 µM and 0.29 ± 0.11 µM, respectively (Table 2). The IC50 values generated with hepatocyte
suspensions were closer to the transfected OATP-derived values, which implies that RSV (0.1
µM) uptake is largely dominated by OATPs.
Impact of CsA on RSV Pharmacokinetics in Cynomolgus Monkeys. To assess the
inhibitory effect of CsA on pharmacokinetics of RSV in vivo, a DDI study was conducted in
male cynomolgus monkeys. The plasma concentrations of RSV were increased significantly
when RSV was co-administered with CsA (Figure 5A), and the pharmacokinetic results are
summarized in Table 3. CsA increased the RSV AUC0-inf by 6.3-fold and Cmax by 10.2-fold
relative to RSV administered alone. The mean CL/F and Vd/F for RSV alone are 784.6 ± 227.3
mL/min/kg and 594.0 ± 216.7 L/kg, respectively. The mean CL/F and Vd/F for RSV when co-
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
25
administered with CsA were 129.8 ± 54.8 mL/min/kg and 48.7 ± 29.1 L/kg, respectively. The t1/2
of RSV decreased with co-administration of CsA (9.1 ± 3.1 hr vs. 4.3 ± 1.3 hr; Table 3).
Urinary excretion of RSV was also increased in the presence of CsA (Figure 6; Table 4).
CsA increased total amount of RSV excreted in urine Xe, 0-48 hr by approximated 6-fold (214.1 ±
81.3 vs. 1234.8 ± 506.3 nmol). However, the renal clearance (CLR) of RSV did not change
significantly with co-administered CsA (Table 4).
At an oral dose of 100 mg/kg Neoral oral solution, CsA blood levels reached a peak of
1.1 ± 0.3 µM, with a tmax of 4.3 ± 0.4 hr (Figure 5B). The AUC over a 49-hr period was 10.0 ±
3.0 µM•hr, with an average concentration of 0.20 µM. The average concentration is comparable
to the IC50 values of CsA obtained from monkey hepatocytes and cOATP-expressing HEK-293
cells. The CsA systemic exposures obtained in this study were comparable to those in patients at
a therapeutic dose (Noartis, 2005) and in monkeys at 50 and 100 mg/kg (Schuurman et al.,
2001).
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
26
Discussion
OATP1B-mediated DDIs are a major concern in drug development and clinical practice
(International Transporter et al., 2010). OATP inhibition likely is not only dose-dependent but
also time-dependent, therefore, the extent and duration of inhibition is dynamic. As a result, a
mechanistic static model will often over-predict a clinical DDI involving OATP inhibition,
especially when assuming that the inhibitor concentration is represented by the maximum
unbound concentration in the portal vein. The cynomolgus monkey model can be used to
examine in vivo DDI, thus bridging the in vitro inhibitory potential to the extent of in vivo
inhibition. However, the assumption is that the pharmacokinetics of probe substrate in monkeys
is similar to that of human subjects. In recent studies, the monkey model has been successfully
applied by investigators to quantitatively predict transport-based DDIs (Shen et al., 2013;
Takahashi et al., 2013). The objective of the current study was to evaluate absorption,
metabolism, and excretion of RSV in cynomolgus monkeys (BDC study), and in vitro and in
vivo inhibitory effects of CsA on the transport of RSV, a probe substrate most commonly used in
clinical DDI studies.
Given that the prediction of DDI of many OATP1B substrates, including RSV, is
complex, requiring input parameters of fraction eliminated via each pathway, we evaluated the
disposition profile of RSV in BDC monkeys using [3H]RSV. Recovery of radioactivity was
complete after 168 h postdose. Excretory profiles of radioactivity in the urine, bile, and feces
suggested that fecal excretion followed by biliary elimination was the major route of elimination
of drug-derived radioactivity (61.7% and 39.0% of dose, respectively; Table 1). Metabolite
profiles in urine and bile were qualitatively similar. Unchanged RSV was detected as the major
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
27
component in both pooled bile and urine from monkeys (62.8% and 45.7% of the radioactivity
were collected in bile and urine, respectively; Figure 1), indicating that RSV did not undergo
extensive metabolism before excretion in monkeys. The radioactivity in plasma was too low to
examine metabolite profile. Unfortunately, the metabolic profile of fecal samples was not
examined. If we assume no significant intestinal secretion and gastrointestinal (GI) metabolism,
the total unchanged RSV recovered in bile and feces would be 86.2% of the dose administered in
BDC monkeys. This is in agreement with what is observed in intact cynomolgus monkeys and
humans (75.0% and 76.8%, respectively; Table 5) (US FDA, 2003; Martin et al., 2003b). The
extent of intestinal secretion of RSV is known to be low in dogs, with 3.3% of radioactive dose
was found in the feces collected from 0 to 72 hr after intravenous (IV) administration of 5 mg/kg
[14C]RSV to BDC dogs (US FDA, 2003). The percentage of RSV absorbed in the BDC
monkeys, estimated by adding the total radioactivity in bile and urine, was at least 41.9%,
suggesting that the compound is reasonably absorbed in monkeys. This is comparable to the oral
absorption fraction estimate of approximately 50% in humans (Table 5) (US FDA, 2003; (Martin
et al., 2003a). Putting these findings together, the similarities observed in absorption, metabolism
and excretion properties between cynomolgus monkey and human suggest that monkey is a
suitable surrogate animal model for further preclinical pharmacokinetic studies for RSV.
Previously, we have reported that cynomolgus monkey is an effective model to assess
investigational drugs for OATP interaction in humans. Moreover, we provided evidence that
RSV-rifampicin (RIF) is an OATP1B probe substrate/reference inhibitor combination applicable
in several assay systems in vitro and in vivo (Shen et al., 2013). In the present study, we
extended the application of the cynomolgus monkey model by validation of RSV-CsA as
OATP1B probe substrate/reference inhibitor combination since CsA is commonly used as a
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
28
clinical OATP1B inhibitor. The potential hepatic transporter-mediated DDI between RSV with
CsA was first investigated in monkey and human OATP1B and NTCP recombinant systems.
CsA inhibited RSV uptake mediated by hOATP1B1 and cOATP1B1, with IC50 values of 0.21 ±
0.10 and 0.28 ± 0.11 μM, respectively (Figure 2A and 2C; Table 2). CsA also inhibited RSV
uptake mediated by hOATP1B3 and cOATP1B3, in a similar potent manner, with IC50 values of
0.13 ± 0.06 and 0.25 ± 0.09 μM, respectively (Figure 2B and 2D; Table 2). Moreover, CsA
decreased RSV uptake mediated by cNTCP in concentration-dependent manner with IC50 value
of 3.9 ± 2.0 μM, which is comparable to that of human NTCP generated from 55 different test
occasions at Bristol-Myers Squibb (Figure 3B; Table 2). Furthermore, the potential hepatic
transporter-mediated DDI between RSV with CsA was investigated in monkey and human
hepatocyte inhibition assays. CsA significantly reduced uptake of RSV in both human and
monkey hepatocytes in a concentration-dependent manner with IC50 values of 0.30 ± 0.08 and
0.29 ± 0.11 μM, respectively (Figure 4 and Table 2). These data are in agreement with the
recombinant data, which showed that CsA inhibited the hOATP1B- and cOATP1B-mediated
transport of RSV with IC50 ranged from 0.13 to 0.28 µM. No attempt was made to study
OATP2B1 inhibition by CsA because previous studies suggested that OATP2B1 is less likely to
play a significant role in RSV disposition in both species. Moreover, CsA was a weak inhibitor
of both monkey and human OATP2B1 (Shen et al., 2013). Similarly, Prueksaritanont et al. have
shown that human OATP2B1 contributed minimally to the hepatic uptake of RSV by RIF
inhibition and DDI data (Prueksaritanont et al., 2014).
Using in vitro transporter inhibition studies as screening tools to evaluate potential for
DDI in vivo is based on the assumption that the victim drugs analyzed share the same transport
kinetics between cynomolgus monkey and human OATP1B. Previous concentration-dependent
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
29
transport studies using stably transfected HEK-293 cells, expressing individual monkey and
human OATP1B1, OAPT1B3, and OATP2B1, indicated that the RSV apparent Km (9.6 to 15.3
µM) is comparable across the three transporters (Shen et al., 2013). The transport kinetics of
RSV in hepatocytes has been examined also. In this instance, the kinetics of RSV uptake were
best described by a mixed model consisting of both a single saturable process and a passive
component, yielding Km of 6.7 and 10.3 µM for monkey and human, respectively, which agreed
well with Km values obtained from the recombinant systems. These studies suggest no species
difference in the transport kinetics of RSV in monkey and human OATP1B1-, OATP1B3-, and
OATP2B1-overexpressing cells and hepatocytes (Shen et al., 2013).
Co-administration of CsA with RSV markedly increased AUC0-inf and Cmax of RSV in
cynomolgus monkey by 6.3-fold and 10.2-fold, respectively (Table 3). After oral administration
of 100 mg/kg CsA, blood concentrations of CsA in the range of 1.1 to 0.05 μM were achieved
for the first 25 hr after CsA administration (the first 24 hr after RSV administration) (Figure 5B).
The Cmax of CsA after a single oral dose in monkeys was comparable to that at steady state after
multiple dosing in patients (1.1 vs. 1.0 µM). Interestingly, the impact of CsA on RSV in
monkeys appeared to be identical to that in heart transplant patients taking CsA (7.1-fold and
10.6-fold for AUC and Cmax, respectively) (Simonson et al., 2004). This finding, although not
unanticipated, suggests cynomolgus monkey is an appropriate model for the assessment of
OATP-mediated DDIs in a nonclinical setting. It is not clear however, if this can be extended to
other substrates of these transporters. First, although cynomolgus monkey OATPs share a high
degree of amino acid sequence identity and functional similarity to their human counterparts,
subtle amino acid differences can greatly impact substrate specificity. For example, DeGorter
and colleagues reported that site-directed mutagenesis of 3 amino acid residues in OATP1B1
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
30
transmembrane domains 1 and 10, and extracellular loop 6, to the corresponding residues in
OATP1B3, resulted in a gain of CCK-8 transport by OATP1B1, which is a high affinity
substrate for OATP1B3 but not OATP1B1 (DeGorter et al., 2012). Second, this IVIVE approach
only makes a reasonable prediction if the relative contribution of OATP-mediated uptake
clearance to the total body clearance and ADME profiles are well understood in both species.
The BDC monkey study indicated that RSV is an appropriate in vivo probe for OATP-mediated
DDI study in monkeys. The conclusions likely extend to pitavastatin. Takahashi and his
colleagues reported that the magnitude of hepatic OATP DDI was comparable between the
monkey study and the clinical study by using pitavastatin as a substrate. They concluded that
pharmacokinetic studies using pitavastatin as a probe in combination with drug candidates in
cynomolgus monkeys are useful to support the assessment of potential clinical DDIs involving
hepatic uptake transporters (Takahashi et al., 2013).
RSV has been shown in vitro to be a substrate of transporters other than OATP1B1,
OATP1B3, and OATP2B1. For example, it has been reported that human NTCP plays an
important role in hepatic uptake of RSV in human hepatocytes (Bi et al., 2013; Ho et al., 2006),
although the relevance of this transporter in vivo has yet to be confirmed. In addition, BCRP and
OAT3 (organic anion transporter 3) may play a role in RSV intestinal absorption and renal
elimination, respectively (Yoshida et al., 2012). In the case of the former, patients expressing the
ABCG2 variant 421C>A, a single-nucleotide polymorphism (SNP) associated with reduced
efflux activity in vitro, showed a 140% increase in RSV exposure (Keskitalo et al., 2009). This
implies that inhibition of intestinal BCRP can also bring about increased RSV exposure.
Therefore, the impact on RSV pharmacokinetics will likely be determined by inhibition of
OATPs, NTCP, BCRP, and OAT3. Consideration of OAT3 has been ruled out in this instance,
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
31
because CsA did not impact the renal clearance of RSV (Table 4). In the present studies, we
report for the first time that CsA is a potent inhibitor of cOATPs and cNTCP (IC50 values of ~
0.3 µM and 3.9 µM, respectively; Table 2). In addition, CsA inhibits these monkey hepatic
transporters to a similar extent compared to the human counterparts. Consistent with human data
also is the marked effect of CsA on RSV exposure when compared to RIF (6.3- to 7.1-fold vs.
2.9- to 4.4-fold increase) (Shen et al., 2013; Simonson et al., 2004). Such results are consistent
with the fact that DDI studies with CsA have been accepted by regulatory agencies as the worst
case scenario for substrates of transporters. While RIF is also a potent inhibitor of OATPs (IC50:
0.42 to 1.69 µM), it is a weaker inhibitor of NTCP (IC50 of 277 uM vs 3.9 uM) and BCRP (IC50
of 14 µM vs. ~7 µM) (Nezasa et al., 2002b; Prueksaritanont et al., 2014; Shen et al., 2013) and
so it is hypothesized that the extent of inhibition of liver basolateral NTCP and OATP, and
intestinal apical BCRP, is greater for CsA (vs. RIF) in monkeys and humans. In addition, the
decreased hepatic uptake could impact the extent of metabolism of RSV.
In summary, an in vitro-in vivo assay system previously used to evaluate the interaction
between RIF with RSV in cynomolgus monkeys was extended to include CsA. Here we
provided further evidence that the disposition of radiolabeled RSV in cynomolgus monkeys is
comparable to that in humans following an oral dose. In addition, the magnitude of the DDI
between CsA and RSV is similar to that reported clinically. Although additional transporter data
are needed for monkey BCRP, the results described herein do suggest that RSV can be a useful
substrate for probing OATP-mediated pharmacokinetics and DDIs in humans and monkeys.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
32
Authorship Contributions
Participated in research design: Shen, Su, Mintier, Iyer, Marathe, Lai and Rodrigues.
Conducted experiments: Shen, Su, Liu, Yao, Mintier and Li.
Contributed new reagents or analytic tools: Shen, Liu, Mintier and Fancher.
Performed data analysis: Shen, Su, Liu, Mintier, Lai and Rodrigues.
Wrote or contributed to the writing of the manuscript: Shen, Marathe, Lai and Rodrigues.
Other: None.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
33
References Bergman, E., A. Lundahl, P. Fridblom, M. Hedeland, U. Bondesson, L. Knutson and H.
Lennernas (2009). Enterohepatic disposition of rosuvastatin in pigs and the impact of
concomitant dosing with cyclosporine and gemfibrozil. Drug Metab Dispos 37(12): 2349-
2358.
Bi, Y. A., X. Qiu, C. J. Rotter, E. Kimoto, M. Piotrowski, M. V. Varma, A. F. Ei-Kattan and Y.
Lai (2013). Quantitative assessment of the contribution of sodium-dependent taurocholate
co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and
fluvastatin. Biopharm Drug Dispos 34(8): 452-461.
Chang, J. H., J. Ly, E. Plise, X. Zhang, K. Messick, M. Wright and J. Cheong (2014).
Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of
atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice. Drug Metab Dispos
42(6): 1067-1073.
DeGorter, M.K., Ho, R.H., Leake, B.F., Tirona, R.G., and Kim, R.B. (2012). Interaction of three
regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate
specificity. Mol Pharma 9: 986-995.
Hagenbuch, B. and P. J. Meier (2004). Organic anion transporting polypeptides of the OATP/
SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new
nomenclature and molecular/functional properties. Pflugers Arch 447(5): 653-665.
Higgins, J. W., J. Q. Bao, A. B. Ke, J. R. Manro, J. K. Fallon, P. C. Smith and M. J. Zamek-
Gliszczynski (2014). Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in
the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with
pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug Metab Dispos
42(1): 182-192.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
34
Ho, R. H., R. G. Tirona, B. F. Leake, H. Glaeser, W. Lee, C. J. Lemke, Y. Wang and R. B. Kim
(2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression,
and pharmacogenetics. Gastroenterology 130(6): 1793-1806.
International Transporter, C., K. M. Giacomini, S. M. Huang, D. J. Tweedie, L. Z. Benet, K. L.
Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. M. Hillgren, K. A. Hoffmaster, T.
Ishikawa, D. Keppler, R. B. Kim, C. A. Lee, M. Niemi, J. W. Polli, Y. Sugiyama, P. W.
Swaan, J. A. Ware, S. H. Wright, S. W. Yee, M. J. Zamek-Gliszczynski and L. Zhang
(2010). Membrane transporters in drug development. Nat Rev Drug Discov 9(3): 215-236.
Iusuf, D., M. Ludwig, A. Elbatsh, A. van Esch, E. van de Steeg, E. Wagenaar, M. van der Valk,
F. Lin, O. van Tellingen and A. H. Schinkel (2014). OATP1A/1B transporters affect
irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and
humanized transgenic mice. Mol Cancer Ther 13(2): 492-503.
Keskitalo, J. E., O. Zolk, M. F. Fromm, K. J. Kurkinen, P. J. Neuvonen and M. Niemi (2009).
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and
rosuvastatin. Clin Pharmacol Ther 86(2): 197-203.
Kitamura, S., K. Maeda, Y. Wang and Y. Sugiyama (2008). Involvement of multiple transporters
in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36(10): 2014-2023.
Klaassen, C. D. and H. Lu (2008). Xenobiotic transporters: ascribing function from gene
knockout and mutation studies. Toxicol Sci 101(2): 186-196.
Li, L., A. Nouraldeen and A. G. Wilson (2013). Evaluation of transporter-mediated hepatic
uptake in a non-radioactive high-throughput assay: a study of kinetics, species difference
and plasma protein effect. Xenobiotica 43(3): 253-262.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
35
Lu, H., S. Choudhuri, K. Ogura, I. L. Csanaky, X. Lei, X. Cheng, P. Z. Song and C. D. Klaassen
(2008). Characterization of organic anion transporting polypeptide 1b2-null mice: essential
role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol Sci 103(1): 35-45.
Martin, P. D., M. J. Warwick, A. L. Dane, C. Brindley and T. Short (2003). Absolute oral
bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25(10):
2553-2563.
Martin, P. D., M. J. Warwick, A. L. Dane, S. J. Hill, P. B. Giles, P. J. Phillips and E. Lenz
(2003). Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male
volunteers. Clin Ther 25(11): 2822-2835.
Nezasa, K., K. Higaki, T. Matsumura, K. Inazawa, H. Hasegawa, M. Nakano and M. Koike
(2002). Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and
simvastatin. Drug Metab Dispos 30(11): 1158-1163.
Nezasa, K., A. Takao, K. Kimura, M. Takaichi, K. Inazawa and M. Koike (2002).
Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor, in rat. Xenobiotica 32(8): 715-727.
Pasanen, M. K., H. Fredrikson, P. J. Neuvonen and M. Niemi (2007). Different effects of
SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin
Pharmacol Ther 82(6): 726-733.
Prueksaritanont, T., X. Chu, R. Evers, S. O. Klopfer, L. Caro, P. A. Kothare, C. Dempsey, S.
Rasmussen, R. Houle, G. Chan, X. Cai, R. Valesky, I. P. Fraser and S. A. Stoch (2014).
Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B
clinical probe than rosuvastatin. Br J Clin Pharmacol 78(3): 587-598.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
36
Salphati, L., X. Chu, L. Chen, B. Prasad, S. Dallas, R. Evers, D. Mamaril-Fishman, E. G. Geier,
J. Kehler, J. Kunta, M. Mezler, L. Laplanche, J. Pang, A. Rode, M. G. Soars, J. D. Unadkat,
R. A. van Waterschoot, J. Yabut, A. H. Schinkel and N. Scheer (2014). Evaluation of
organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational
model to study the pharmacokinetics of statins. Drug Metab Dispos 42(8): 1301-1313.
Schneck, D. W., B. K. Birmingham, J. A. Zalikowski, P. D. Mitchell, Y. Wang, P. D. Martin, K.
C. Lasseter, C. D. Brown, A. S. Windass and A. Raza (2004). The effect of gemfibrozil on
the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75(5): 455-463.
Schuurman, H. J., W. Slingerland, K. Mennninger, M. Ossevoort, J. C. Hengy, B. Dorobek, J.
Vonderscher, J. Ringers, M. Odeh and M. Jonker (2001). Pharmacokinetics of cyclosporine
in monkeys after oral and intramuscular administration: relation to efficacy in kidney
allografting. Transpl Int 14(5): 320-328.
Shen, H., Z. Yang, G. Mintier, Y. H. Han, C. Chen, P. Balimane, M. Jemal, W. Zhao, R. Zhang,
S. Kallipatti, S. Selvam, S. Sukrutharaj, P. Krishnamurthy, P. Marathe and A. D. Rodrigues
(2013). Cynomolgus monkey as a potential model to assess drug interactions involving
hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo
extrapolation. J Pharmacol Exp Ther 344(3): 673-685.
Shirasaka, Y., E. Kuraoka, H. Spahn-Langguth, T. Nakanishi, P. Langguth and I. Tamai (2010).
Species difference in the effect of grapefruit juice on intestinal absorption of talinolol
between human and rat. J Pharmacol Exp Ther 332(1): 181-189.
Shitara, Y., A. P. Li, Y. Kato, C. Lu, K. Ito, T. Itoh and Y. Sugiyama (2003). Function of uptake
transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human
hepatocytes. Drug Metab Pharmacokinet 18(1): 33-41.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
37
Simonson, S. G., A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass
and D. W. Schneck (2004). Rosuvastatin pharmacokinetics in heart transplant recipients
administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76(2):
167-177.
Takahashi, T., T. Ohtsuka, T. Yoshikawa, I. Tatekawa, Y. Uno, M. Utoh, H. Yamazaki and T.
Kume (2013). Pitavastatin as an in vivo probe for studying hepatic organic anion
transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys. Drug
Metab Dispos 41(10): 1875-1882.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug
Evaluation and Research (CDER). Approval package for Crestor (rosuvastatin calcium).
US FDA website http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-
366_Crestor_Pharmr_P2.pdf, (2003).
van de Steeg, E., C. M. van der Kruijssen, E. Wagenaar, J. E. Burggraaff, E. Mesman, K. E.
Kenworthy and A. H. Schinkel (2009). Methotrexate pharmacokinetics in transgenic mice
with liver-specific expression of human organic anion-transporting polypeptide 1B1
(SLCO1B1). Drug Metab Dispos 37(2): 277-281.
Wang, L., Prasad, B., Salphati, L., Chu, X., Gupta, A., Hop, C.E., Evers, R., and Unadkat, J.D.
(2015). Interspecies Variability in Expression of Hepatobiliary Transporters across Human,
Dog, Monkey, and Rat as Determined by Quantitative Proteomics. Drug Metab Dispos 43:
367-374.
Wen, J. H. and Y. Q. Xiong (2011). The effect of herbal medicine danshensu and ursolic acid on
pharmacokinetics of rosuvastatin in rats. Eur J Drug Metab Pharmacokinet 36(4): 205-211.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
38
Yoshida, K., K. Maeda and Y. Sugiyama (2012). Transporter-mediated drug--drug interactions
involving OATP substrates: predictions based on in vitro inhibition studies. Clin
Pharmacol Ther 91(6): 1053-1064.
Zaher, H., H. E. Meyer zu Schwabedissen, R. G. Tirona, M. L. Cox, L. A. Obert, N. Agrawal, J.
Palandra, J. L. Stock, R. B. Kim and J. A. Ware (2008). Targeted disruption of murine
organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters
disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74(2):
320-329.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
39
Footnotes
Reprint requests: Hong Shen, F1.3802, Route 206 & Province Line Road., Bristol-Myers Squibb
Company, Princeton, NJ 08543. Telephone: (609) 252-4509; Facsimile: (609) 252-6802
This study is supported by Bristol-Myers Squibb Company.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
40
Figure Legends
Fig. 1. Representative radiochromatogram of pooled bile (A) and urine (B) from samples taken
72 and 168 hours after administration of a single oral dose of [3H]RSV at 3 mg/kg to bile-duct
cannulated cynomolgus monkeys. Samples were profiled with HPLC method. The retention time
for RSV was approximately 32 min. The % (of the radioactivity collected in bile or urine
samples) as parent RSV is indicated.
Fig. 2. Effect of CsA on the uptake of RSV (0.1 µM) in hOATP1B1-, hOATP1B3-,
cOATP1B1-, and cOATP1B3-HEK cells. The transporter-mediated uptake was obtained by
subtracting the transport rate during the first 2 min incubation at 37°C in vector control cells
from that in transporter-transfected cells. The data are expressed as a percentage of initial uptake
rate in the presence and absence of CsA. IC50 values were obtained by fitting the uptake data to
the equation (see Materials & Methods) and are summarized in Table 2. Values shown are mean
± S.D. for experiments performed in triplicate.
Fig. 3. Uptake of [3H]TCA, [3H]RSV and [3H]ATV in mock- and cNTCP-HEK cells was
determined after 5 minutes of incubation (A). Each value represents the mean ± SD (n = 3). ***p
< 0.001, uptake was significantly different from Mock-HEK cells. B, effect of CsA on cNTCP-
mediated uptake of RSV (0.1 µM) was determined by subtracting the transport rate during the
first 2 min incubation at 37°C in vector control cells from that in transporter-transfected cells in
the presence of various concentrations of CsA. The data are expressed as a percentage of initial
uptake rate in the presence and absence of CsA. IC50 values were obtained by fitting the uptake
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
41
data to either the equation (see Materials & Methods) and are summarized in Table 2. Values
shown are mean ± S.D. for experiments performed in triplicate.
Fig 4. Effect of CsA on the uptake of [3H]RSV (0.1 µM) by human and cynomolgus monkey
hepatocytes. The data are expressed as a percentage of initial uptake rate measured at 15 and 90
seconds at 37°C in the presence and absence of CsA. IC50 values were obtained by fitting the
uptake data to the equation (see Materials & Methods) and are summarized in Table 2. Values
shown are mean ± S.D. for experiments performed in triplicate.
Fig. 5. Mean plasma concentrations of RSV (A) and whole blood concentrations of CsA (B)
after single oral dose of RSV (3 mg/kg) alone (open circle) or with CsA (100 mg/kg, PO) (solid
circle or triangle) in cynomolgus monkeys. Inset in figure A depicts same data on semi-
logarithmic scale. CsA was dosed one hour ahead of RSV. Data are expressed as mean ± S.D. (n
= 3 animals).
Fig. 6. Effects of CsA on urinary exertion of RSV after single oral dose of RSV (3 mg/kg) alone
or with CsA (100 mg/kg, PO) in cynomolgus monkeys. The amount of RSV excreted in urine in
monkeys was determined for the RSV alone (open bar) and CsA-treated (closed bar) groups.
CsA was dosed one hour ahead of RSV. Data are expressed as mean ± S.D. (n = 3 animals).
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
42
Table 1
Cumulative excretion of radioactivity in the bile, urine and feces of bile-cannulated cynomolgus
monkeys (n = 3) after a single oral administration of [3H]RSV
Collection Interval (hr)
Excretion of Radioactivity (% of Dose)
Bile Urine Feces
0-8 20.8 ± 7.3 0.9 ± 0.3 NS** 8-24 13.5 ± 4.4 0.7 ± 0.2 30.1 ± 5.5 24-72 4.7 ± 2.9 0.8 ± 0.5 20.5 ± 17.0 72-168 NS* 0.6 ± 0.3 11.2 ± 12.4 0-168 39.0 ± 3.0 2.9 ± 1.3 61.7 ± 25.1 Total Recovery 103.6 ± 27.5
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
43
Table 1 Legend:
*Only 0 to 72 hr bile samples were collected and analyzed
**Only 0 to 24 hr fecal samples were collected and analyzed
Data reported as mean ± S.D., n = 3 different animals.
NS, no sample
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
44
Table 2
In vitro evaluation of CsA as an inhibitor of RSV uptake into hepatocytes and
HEK-293 cells expressing individual transporter
IC50 (µM)*
Hepatocytes OATP1B1 OATP1B3 NTCP
Human 0.30 ± 0.08 0.21 ± 0.10 0.13 ± 0.06 2.1 ± 0.9**
Cynomolgus Monkey 0.29 ± 0.11 0.28 ± 0.11 0.25 ± 0.09 3.9 ± 2.0
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
45
Table 2 Legend:
*IC50 values were generated at a low concentration of RSV (0.1 µM) and data are represented as
the mean ± SD (n = 3 determinations) (see Materials and Methods).
**IC50 was average of the values generated from 55 different test occasions using [3H]TCA (1
μM) as probe substrate.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
46
Table 3
Pharmacokinetics of RSV and CsA after a single oral dose of 3 mg/kg RSV with and without
100 mg/kg oral CsA in cynomolgus monkeys
Parameter RSV Alone CsA + RSV* GMR (90% CI)
RSV
Cmax (nM) 14.3 ± 5.2 145.5 ± 53.1 10.2 (3.3-31.9)
tmax (hr) 2.7 ± 0.6 2.7 ± 0.6
t1/2 (hr) 9.1 ± 3.1 4.3 ± 1.3
AUC0-inf (nM•hr) 133.9 ± 34.5 897.5 ± 462.0 6.3 (3.1-12.9)
CsA*
Cmax (µM) 1.1 ± 0.3
tmax (hr) 4.3 ± 1.5
t1/2 (hr) 5.9 ± 0.4
AUC0-49 (µM•hr) 10.0 ± 3.0
C25 hr (µM) 0.05 ± 0.01
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
JPET 221804
47
Table 3 Legend:
*CsA was dosed one hr prior to RSV (see Materials and Methods).
Data reported as mean ± S.D., n = 3 different animals.
GMR geometric mean ratio; CI confidence interval; Cmax maximum concentration; Tmax time of
Cmax; t1/2 terminal elimination half-life; AUC0-inf area under the concentration-time curve from
time zero to infinity, C25 hr concentration 25 hr post-dose.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
Table 4
Urinary excretion of RSV after a single oral dose of 3 mg/kg RSV with and without 100 mg/kg oral CsA in cynomolgus monkeys
Parameter Animal 1 Animal 2 Animal 3 Average
RSV Alone
CsA + RSV RSV
Alone CsA + RSV RSV
Alone CsA + RSV RSV Alone CsA + RSV
Bodyweight (kg) 3.4 3.4 3.9 3.7 4.1 4.2 3.8 ± 0.4 3.8 ± 0.4
Xe, 0-48 hr (nmol) 120.6 925.1 253.9 1819.0 267.9 960.2* 214.1 ± 81.3 1234.8 ± 506.3
Xe, 0-48 hr (% dose) 0.6 4.5 1.1 8.1 1.1 3.8* 0.92 ± 0.29 5.5 ± 2.3
AUC0-inf (nM*hr) 95.8 706.3 162.9 1424.4 143.0 561.8 133.9 ± 34.5 897.5 ± 462.0
CLR (mL/min/kg) 6.1 6.3 6.7 5.7 7.6 6.8* 6.8 ± 0.7 6.3 ± 0.6
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on M
arch 4, 2015 as DO
I: 10.1124/jpet.114.221804 at ASPET Journals on August 20, 2020 jpet.aspetjournals.org Downloaded from
JPET 221804
49
Legend to Table 4:
*The urine sample collected between 0 to 7 hr from animal 3 was contaminated, the amount of RSV excreted into urine during the
interval was not included into the cumulative excretion.
Data reported as mean ± S.D., n = 3 different animals.
Xe, 0-48 hr is the amount or percentage of RSV recovered in urine over 48 hr; CLR renal clearance.
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on M
arch 4, 2015 as DO
I: 10.1124/jpet.114.221804 at ASPET Journals on August 20, 2020 jpet.aspetjournals.org Downloaded from
JPET 221804
50
Table 5
Percentage of dose recovery in monkeys and humans after oral administration of radio-labeled RSV
Species Oral Dose % Dose
Urine (parent) Feces (parent) Bile (parent) Total recovery Reference
BDC monkey 3 mg/kg 2.9 (1.3) 61.7 (ND) 39 (24.5) 103.6
Intact monkey 10 mg/kg 5.0 (1.0) 90.7 (75.0) 95.7 US FDA, 2003
Human 20 mg 10.6 (4.9) 90.0 (76.8) 100.6 Martin et al., 2003a
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on M
arch 4, 2015 as DO
I: 10.1124/jpet.114.221804 at ASPET Journals on August 20, 2020 jpet.aspetjournals.org Downloaded from
JPET 221804
51
Legend to Table 5:
ND not determined; BDC bile duct cannulated.
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on M
arch 4, 2015 as DO
I: 10.1124/jpet.114.221804 at ASPET Journals on August 20, 2020 jpet.aspetjournals.org Downloaded from
1450
min
)
RSV (62.8%)(A) Bile (0-72 hr)
450
950
ivity
(cou
nts/
-50
450
0 5 10 15 20 25 30 35 40 45 50
Radi
oact
Time (min)
195
min
)
RSV (45 7%)(B) Urine (0-168 hr)
95
145
ivity
(cou
nts/
m RSV (45.7%)
-5
45
0 5 10 15 20 25 30 35 40 45 50
Radi
oact
i
Time (min)
Figure 1
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on M
arch 4, 2015 as DO
I: 10.1124/jpet.114.221804 at ASPET Journals on August 20, 2020 jpet.aspetjournals.org Downloaded from
140
Observed Fitted
140
Observed Fitted
6080
100120140
1-M
edia
ted
RSV
te (%
of C
ontr
ol) (A)
6080
100120140
3-M
edia
ted
RSV
te (%
of C
ontr
ol) (B)
02040
0.00 0.01 0.10 1.00 10.00 100.00
hOA
TP1B
1U
ptak
e R
at
CsA Concentration (µM)
02040
0.00 0.01 0.10 1.00 10.00 100.00
hOA
TP1B
3U
ptak
e R
at
CsA Concentration (µM)CsA Concentration (µM) CsA Concentration (µM)
140)
Observed Fitted
140)
Observed Fitted
6080
100120140
1-M
edia
ted
RSV
te (%
of C
ontr
ol) (C)
6080
100120140
3-M
edia
ted
RSV
te (%
of C
ontr
ol) (D)
02040
0.00 0.01 0.10 1.00 10.00 100.00
cOA
TP1B
Upt
ake
Ra
CsA Concentration (µM)
02040
0.00 0.01 0.10 1.00 10.00 100.00
cOA
TP1B
Upt
ake
Ra
CsA Concentration (µM)
Figure 2
CsA Concentration (µM) CsA Concentration (µM)
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
JPET
Fast Forward. Published on M
arch 4, 2015 as DO
I: 10.1124/jpet.114.221804 at ASPET Journals on August 20, 2020 jpet.aspetjournals.org Downloaded from
120
140
d R
SVC
ontr
ol)
Observed Fitted
(B)
20
40
60
80
100
cNTC
P-M
edia
ted
Upt
ake
Rat
e (%
of C
00.00 0.01 0.10 1.00 10.00 100.00
U
CsA Concentration (µM)
Figure 3
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
(A)120
140
by H
uman
C
ontr
ol)
Observed Fitted
20
40
60
80
100
]RSV
Upt
ake
Rat
e b
Hep
atoc
ytes
(% o
f C
0
20
0.0 0.1 1.0 10.0 100.0
[3H
] H
CsA Concentration (µM)
(B)120
140
Mon
key
trol
)
Observed Fitted
40
60
80
100
V U
ptak
e R
ate
by M
atoc
ytes
(% o
f Con
t
0
20
0.0 0.1 1.0 10.0 100.0
[3H
]RS
Hep
CsA Concentration (µM)
Figure 4
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
200
250(n
M)
(A)100
1,000
atio
n (n
M)
100
150
V C
once
ntra
tion
0
1
10
0 6 12 18 24 30 36 42 48R
SV C
once
ntra
Time (hr)
0
50
0 6 12 18 24 30 36 42 48
RSV
Time (hr)
1.00
10.00
n (µ
M)
(B)
0.01
0.10
sA C
once
ntra
tion
0.000 6 12 18 24 30 36 42 48
Cs
Time (hr)
Figure 5
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from
2000RSV alone
CsA + RSV
500
1000
1500
X e (n
mol
)
00-7 7-24 24-48 0-48
Collection Interval (hr)
Figure 6Figure 6
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on March 4, 2015 as DOI: 10.1124/jpet.114.221804
at ASPE
T Journals on A
ugust 20, 2020jpet.aspetjournals.org
Dow
nloaded from